NCT01802684View on ClinicalTrials.gov

OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

June 30, 2016

Conditions
Unresectable Metastatic Colorectal Cancer
Interventions
BIOLOGICAL

aflibercept

Aflibercept (VEGF Trap) Recombinant human protein, at 25 mg/ml Dose : 4 mg/Kg -Day 1, q2w Route of administration: Intravenous (60 min infusion)

Trial Locations (8)

33300

Polyclinique de Bordeaux Nord, Bordeaux

40000

CH Mont de Marsan, Paris

69008

Hôpital Privé Jean Mermoz, Lyon

75012

Hôpital Saint-Antoine, Paris

75013

Hôpital Pitié Salpêtrière, Paris

75014

Institut Mutualiste Montsouris, Paris

87042

CHU Dupuytren, Limoges

94010

Hôpital Henri Mondor, Créteil

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

GERCOR - Multidisciplinary Oncology Cooperative Group

OTHER